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Summary
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of
randomized clinical trials. The typical analysis uses the same method employed for the intention-
to-treat analysis (e.g., standard survival analysis) applied to the subgroup meeting protocol
adherence criteria. However, due to potential post-randomization selection bias, this analysis may
mislead about treatment efficacy. Moreover, while there is extensive literature on methods for
assessing causal treatment effects in compliers, these methods do not apply to a common class of
trials where a) the primary objective compares survival curves, b) it is inconceivable to assign
participants to be adherent and event-free before adherence is measured, and c) the exclusion
restriction assumption fails to hold. HIV vaccine efficacy trials including the recent RV144 trial
exemplify this class, because many primary endpoints (e.g., HIV infections) occur before
adherence is measured, and nonadherent subjects who receive some of the planned immunizations
may be partially protected. Therefore, we develop methods for assessing per-protocol treatment
efficacy for this problem class, considering three causal estimands of interest. Because these
estimands are not identifiable from the observable data, we develop nonparametric bounds and
semiparametric sensitivity analysis methods that yield estimated ignorance and uncertainty
intervals. The methods are applied to RV144.
Keywords
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1. Introduction
Over the past 30 years, millions of individuals have acquired HIV and the global rate of new
infections remains high. Unfortunately, the development of an HIV vaccine has been
difficult with clinical trials not yielding promising results. However, a recent community-
based, individually-randomized, multicenter, double-blind, placebo-controlled clinical trial
of 16,395 HIV negative volunteers in Thailand (the RV144 `Thai trial') supported that an
HIV vaccine regimen had partial efficacy to reduce the risk of HIV infection (Rerks-Ngarm
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vaccine (or placebo) at the Week 0, 4, 12, 24 study visits, plus two injections of a
recombinant glycoprotein 120 subunit vaccine (or placebo) at the Week 12, 24 study visits,
and monitored participants for the primary endpoint of HIV infection from entry until the
final study visit at 3.5 years. While the Thai trial's finding of partial efficacy generated great
enthusiasm as the first positive finding from an HIV vaccine efficacy trial, it also generated
confusion, because the results on vaccine efficacy appeared to differ depending on whether
the analysis utilized the modified intention-to-treat (MITT) or per-protocol (PP) cohort,
where the MITT cohort was all randomized subjects HIV negative at baseline (determined
via blinded procedures), and the PP cohort was the subset of the MITT cohort that tested
HIV negative at the Week 24 study visit and received all 6 study injections at the Week 0, 4,
12, 24 study visits within pre-specified allowable visit windows. With vaccine efficacy (VE)
defined as the percent reduction in the cumulative probability of HIV infection diagnosis by
39 months post-randomization (vaccine versus placebo), estimated based on Kaplan-Meier
estimates, the MITT result was  = 31%, 95% CI 0% to 51%, p = 0.04 and the PP result
was  = 25%, 95% CI −16% to 51%, p = 0.19. While the point estimates were fairly close
to one another and hence there was little evidence for different effects, nonetheless many
observers expressed concern that VE was apparently lower in the PP cohort.
Due to randomization, the comparator groups in the MITT analysis are guaranteed to have
balanced baseline prognostic factors on average, such that the MITT analysis provides
consistent estimation of a causally-interpretable VE parameter, namely the percent reduction
in the cumulative risk of infection if everyone were assigned vaccine compared to if
everyone were assigned placebo. On the other hand, the comparator groups in the PP
analysis are subsets of randomized subjects whose membership is determined conditional on
post-randomization variables, resulting in possible selection bias (Rosenbaum, 1984), such
that the PP analysis does not necessarily assess a causal effect of vaccination. Rather, it
assesses a mixture of the effect of vaccine assignment and imbalanced prognostic factors
created by conditioning on qualification into the PP cohort. The PP analysis included 24%
fewer subjects and 31% fewer primary endpoint events than the MITT analysis. Table 1
summarizes the reasons why MITT subjects failed to qualify for the PP cohort. The rate of
nonadherence to study injections was significantly higher in the vaccine than placebo group
(24% versus 21%, Chi-squared test p < 0.001), possibly due to a higher rate of
reactogenicity in the vaccine group (79% versus 59%) (Rerks-Ngarm et al. 2009).
As discussed in Gilbert et al. (2011), opinions varied on the interpretation of the results,
ranging from discounting the PP analysis because only the MITT analysis provides an
asymptotically unbiased answer to a question of clear interest (typically statisticians), to
discounting any inference about positive vaccine efficacy because one would expect the
vaccine to work better in those who received all of the immunizations (typically non-
statisticians). In our view, the former interpreters are correct that the problematic
interpretation of the PP analysis renders it of marginal value, whereas the latter interpreters
are correct that, were V E in vaccine-adherent subjects to be assessed in a more meaningful
way, it would indeed add value.
To improve upon the standard analysis of V E in the PP cohort, an analytic method that
adjusts for subject factors known to predict PP cohort membership and HIV infection (such
factors may cause selection bias) should be applied (e.g., see Tsiatis et al. 2008), which in
addition to correcting for bias can improve statistical power by leveraging prognostic
factors. Moreover, because some biasing factors may be unmeasured, the sensitivity of
results to such factors should also be investigated. However, existing approaches to
sensitivity analysis do not directly apply to vaccine efficacy trials, or, more generally, to
two-arm randomized trials of treatments where the primary objective compares survival
curves, some participants experience the primary endpoint before adherence is evaluated,
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and some subjects have partial adherence (implying that the exclusion restriction assumption
is implausible; see Section 3 for the definition and interpretation of this assumption in our
context). Therefore in this article we develop methods for this class of trials. The methods
apply to most vaccine efficacy trials, given that almost all such trials assess per-protocol V E
(Horne, Lachenbruch, and Goldenthal, 2001), and typically multiple immunizations are
administered over a period of months during which disease events occur. Moreover, over the
past several decades the standard non-causal per-protocol analysis has been ubiquitously
applied to such efficacy trials, and this work aims to help improve the standard approach by
adding causal assessment.
This manuscript is organized as follows. In Section 2 we define notation and three PP
treatment effect estimands, and place the current work in the context of previously
developed methodology for evaluating causal effects in compliers. In Section 3 assumptions
are given that help identify the estimands under four different assumption sets. In Sections 4
and 5 we describe non- and semi-parametric methods for inference including techniques for
estimating ignorance and uncertainty intervals. The methods are developed under multiple
assumption sets so that practitioners may tailor the sensitivity analysis approach to their
particular trial; where stronger assumptions are warranted the estimated ignorance and
uncertainty intervals will tend to be narrower. In Section 6 we apply the methods to the Thai
trial. The methods are implemented using the sensitivityPStrat package in R available on
CRAN and our complete analysis code is posted at the second author's website.
2. Notation, Per-Protocol Estimands, and Problem Context
Consider a two-group randomized trial, wherein subjects are randomly assigned to treatment
Z = 1 or Z = 0 (in our motivating example Z = 1 is vaccine and Z = 0 is placebo) and are
followed for the primary time-to-event endpoint (typically a disease event). Let T be the
time from randomization until the disease event and C be the censoring time, such that X =
min(T, C) and Δ = I(T ≤ C) are observed. Let A be an indicator of adherence/compliance to
assigned treatment defined based on study visits between randomization through time τ0.
For example, in the Thai trial, study injections were scheduled at Week 0, 4, 12, 24 visits,
and A = 1 was defined as receipt of all planned injections within the pre-specified allowable
visit windows. Note that A = 1 for Z = 1 subjects indicates appropriate receipt of vaccination
injections whereas A = 1 for Z = 0 subjects indicates appropriate receipt of placebo
injections. We treat A as undefined if T ≤ τ0, denoted by A = *, and assume the data are iid
observations Oi = (Zi, Xi, Δi, Ai), i = 1,…, n.
The population of interest for inference is disease-free and adherent up to τ0. Thus, the PP
cohort of interest is {i : Ti > τ0, Ai = 1}, and we define P P = I(T > τ0, A = 1). Let
 be the survival function in the PP cohort if
assigned treatment Z = z for t ≥ τ0, and . Also let
 and . It is widespread in clinical
trials to measure per-protocol treatment efficacy by a contrast in  and ,
which does not measure a causal effect. Below we define three survival causal effect (SCE)
estimands that account for adherence/compliance.
The first estimand of interest is based on the literature for assessing causal treatment effects
in “always compliers,” “always infected,” or “always survivors” (Angrist, Imbens, and
Rubin, 1996; Frangakis and Rubin, 2002; Shepherd, Gilbert, and Lumley, 2007; Shepherd,
Gilbert, and Dupont, 2011, henceforth SGD). Let T(z),C(z),X(z),Δ(z),A(z) be the potential
outcomes of T,C,X,Δ,A under assignment Z = z for z = 0, 1. Let Sz(t) ≡ P(T(z) > t), Fz(t) ≡
1−Sz(t), and PP(z) ≡ I(T(z) > τ0,A(z) = 1), and set ppz ≡ P(PP(z) = 1). For x, y ∈ [0, 1] let
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h(x, y) be a known contrast function satisfying h(x, x) = 0 and h(x1, y1) ≤ h(x2, y2) for all x1
≤ x2 and y1 ≥ y2, such as h(x, y) = x − y or 1 − (1 − x)/(1 − y).
With the always-compliers approach, the survival causal effect estimand is
(1)
where  for z = 0, 1. The estimand SCEAPP (t)
measures the causal treatment effect in “always per-protocol” (APP) subjects, {PP(1) =
PP(0) = 1}, i.e., subjects who would survive to τ0 under both treatments and would be
compliant to whatever they were assigned. One appeal of this estimand is that always
compliers may be persuaded to follow a treatment policy.
The second survival causal effect estimand of interest is
(2)
where , T(0) > τ0,A(1) = 1) for z =
0, 1, which evaluates “always survivors” (AS) to time τ0 who would be adherent under Z =
1. This estimand differs from SCEAPP (t) by measuring treatment efficacy in those adherent
to treatment 1, regardless of whether they would adhere to treatment 0. This subpopulation
is of interest because, once a treatment is licensed, treatment decisions and policies will
largely be based on the predicted effect of that treatment for those who take it, whereas
adherence to a control preparation may no longer be relevant. Follmann (2000) and Loeys
and colleagues cited below studied the same subpopulation of “would-be treatment
compliers.” We view the APP and ASA1 estimands as complementary, each of interest in its
own right and capturing different information.
While there is a rich literature for assessing causal treatment effects in always compliers or
would-be treatment compliers, most papers have not accommodated an outcome subject to
censoring, and, among those that do, an assumption is made that renders the method
inapplicable in our context. Cuzick et al. (2007) developed a structural proportional hazards
model (SPHM) for estimating a hazard ratio estimand in the APP subpopulation; however,
they assume adherence status A is known at randomization. Closer to our setting in
assuming A is measured after randomization, Loeys and Goetghebeur (2003) and Loeys,
Goetghebeur, and Vandebosch (2005) developed an SPHM for estimating a hazard ratio
estimand in the ASA1 subpopulation assuming all-or-none or time-constant adherence and
A(0) = 1 for all subjects, in which case the method equivalently applies to the APP
subpopulation. This work does not apply to our setting because it assumes the exclusion
restriction, and because we are specifically interested in comparing survival curves, which
allows assessing treatment efficacy over time and avoids the built-in selection bias of hazard
ratios (Hernán, 2010). Baker (1998) and Nie, Cheng, and Small (2011) developed
nonparametric likelihood estimation-based approaches for the APP estimand, but, in
requiring the exclusion restriction, they also do not apply. SGD provided an applicable
approach for the APP estimand (1) that does assume the exclusion restriction, and a novel
contribution of this article is to extend SGD to new identifiability assumption sets that are
sometimes reasonable in double-blinded randomized trials.
The third survival causal effect estimand we study is
(3)
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where  for z = 0, 1, which evaluates the PP cohort under
treatment 1. This estimand addresses the question: “What is the treatment efficacy for the
subpopulation that would satisfy the PP-criteria if assigned treatment 1?” We are unaware of
statistical methods for this estimand, perhaps in part because the estimand in a sense favors
treatment 1, as by definition , and hence treatment 1 starts out at least as good
as treatment 0. Moreover, when T(1) and T(0) are not perfectly correlated, it is easy to find
examples where there is no marginal causal treatment effect on T, but there is an expected
beneficial treatment effect  for all t > τ0 (see Supplementary Materials,
Section 1). Despite this issue, we include this estimand because the per-protocol cohort
under study can be directly observed for the treatment 1 group, and it addresses a question of
interest for treatment 1 PP subjects: “Compared to their observable survival experience,
what would their survival experience have been had they been assigned treatment 0?”
3. Assumption Sets
Throughout we make the “base set” of assumptions made for randomized clinical trials:
Stable Unit Treatment Values (SUTVA), Ignorable Treatment Assignment (Z ⊥ T(1), T(0),
C(1), C(0), A(1), A(0)), and Random Censoring (T(z) ⊥ C(z) for z = 0, 1), where ⊥ denotes
independence. SUTVA states that potential outcomes for each subject i are unrelated to the
assignment Zj of other subjects and that there are not multiple versions of treatment. We also
consider additional assumptions involving the initial study period through τ0, which will be
utilized to help identify the estimands.
Survival Monotonicity (SM): P(T(1) ≤ τ0 < T(0)) = 0
Adherence Monotonicity (AM): P(A(1) = 1, A(0) = 0|T(1) > τ0, T(0) > τ0) = 0
Equal Adherence (EA): P(A(1) = A(0)|T(1) > τ0, T(0) > τ0) = 1
SM states that individuals who would survive beyond τ0 if assigned Z = 0 would also
survive beyond τ0 if assigned Z = 1. Examples of trials where SM may hold are placebo-
controlled trials and non-inferiority trials. AM states that for individuals surviving beyond τ0
under both assignments, those who would adhere under assignment Z = 1 would also adhere
under assignment Z = 0. Adherence requires retention and receipt of treatment through τ0,
such that AM assumes that all subjects retained and adherent through τ0 under Z = 1 would
also be retained and adherent through τ0 under Z = 0. For a double-blinded trial, differential
drop-out and adherence would likely be due to differential side effects, such that AM is
plausible if side effects are as or more likely for Z = 1 than for Z = 0. Here the double-
blinding may be crucial, as it implies there should not be less adherence in the control group
due to a preference to receive treatment. The stronger assumption EA states that all subjects
retained and adherent under one assignment would also be so under the other. While this is
implausible for trials of treatments with serious side effects, it may be plausible for double-
blinded trials of non-toxic interventions in healthy populations (e.g., prevention trials).
We consider four types of assumption sets under which sensitivity analysis techniques are
developed: (A) base set; (B) base set plus AM; (C) base set plus (SM, AM); (D) base set
plus (SM, EA). These sets posit increasingly stringent assumptions. SM, AM, and EA can be
rejected based on data (e.g., SM is rejected if a test indicates S1(τ0) < S0(τ0) in any baseline
subgroup), but they cannot be fully verified, given that they must hold for every individual.
Supplementary Table 1 describes the basic principal strata (Frangakis and Rubin, 2002)
formed based on T(1), T(0), A(1), A(0), as well as the subpopulations defining the
estimands under the assumption sets.
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Given the relatedness of our problem with causal inference for compliers, it is note-worthy
that we do not consider the exclusion restriction assumption that is commonly made. In our
context this assumption is expressed as P(T(1) = T(0)|T(1) > τ0, T(0) > τ0, A(1) = A(0) = 0)
= 1, i.e., the treatment has no effect in individuals non-adherent under each treatment
assignment. This assumption may be plausible in settings with all-or-none adherence, for
which A(1) = 0 indicates no receipt of treatment whatsoever. However, in vaccine trials,
several immunizations are planned and many subjects with A(1) = 0 receive some or even
all immunizations (as for the Thai trial, see Table 1), and hence could have a beneficial
vaccine effect on infection (i.e., T(1) > T(0)). Also, unlike SM, AM, EA, the exclusion
restriction would require making an assumption about the time period after τ0.
4. Semiparametric Sensitivity Analysis and Nonparametric Bounds
We develop semiparametric modeling approaches to sensitivity analysis for each estimand
under each assumption set, which use a fixed sensitivity parameter(s) γ (not identifiable
from the observed data and the base set of assumptions) within a specified region Γ;
accordingly , , and SCE#(t; γ) are indexed by γ ∈ Γ, where # denotes APP,
ASA1, or PP1. We also develop nonparametric bounds, obtained by setting the sensitivity
parameter(s) to extreme values. Our approach follows Robins (1997) and Vansteelandt et al.
(2006), where each estimand is nonparametrically identified once the sensitivity
parameter(s) γ indexing the full data law  defined by modeling restrictions is fixed,
and the goal is inference on the estimand under the union model ,
assuming the true value γ0 of γ lies in Γ.
4.1. Estimands  and 
Assumption set A. As noted above, we will adapt the general sensitivity analysis method of
SGD for making inferences about the APP estimand. The base set of assumptions plus the
following three selection models (and the observed data) identify  and :
B.1: P(PP(1) = 1|PP(0) = 1, T(0) = t) = w0(t; α0, β0) for t > τ0, where w0(t; α0, β0) = G0 {α0
+ h0 (t; β0)}, β0 is a fixed and known parameter, G0 (·) is a known cdf, α0 is an unknown
parameter, and for each β0, h0 (t; β0) is a known function of t.
B.2: P(PP(0) = 1|PP(1) = 1, T(1) = t) = w1(t; α1, β1) for t > τ0, where w1(t; α1, β1) = G1 {α1
+ h1 (t; β1)}, β1 is a fixed and known parameter, G1 (·) is a known cdf, α1 is an unknown
parameter, and for each β1, h1 (t; β1) is a known function of t.
B.3: πAPP ≡ P(PP(1) = PP(0) = 1) is fixed and known.
B.1 models the dependency of PP(1) on the failure time T(0) in the {PP = 1, Z = 0}
subgroup, and B.2 posits a similar model with the treatment assignments swapped. The
parameters γ = (β0, β1, πAPP) are not identified by the observed data; they are sensitivity
parameters, treated as known in a single analysis and varied over a range of values to form a
sensitivity analysis (Scharfstein, Rotnitzky, and Robins, 1999). Following SGD, we specify
each wz(t; αz, βz) for z = 0, 1 with a modified inverse logit function,
(4)
where τ > τ0 is some number less than or equal to the maximum length of follow-up. The
minimum of t and τ is used instead of t to avoid parametric assumptions about  and
 beyond the support of the data. Based on (4), β0 is the log odds ratio of meeting the
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PP-criteria under treatment Z = 1 per unit increment of T(0) for subjects who meet the PP-
criteria under treatment Z = 0. This parameter is interpreted for per-protocol placebo
recipients with different infection times if not vaccinated, T(0), which reflects their risk for
infection. As such, β0 = 0 implies that the odds of being per-protocol if vaccinated is not
associated with infection risk in per-protocol placebo recipients. If β0 > 0 (β0 < 0), then the
odds of being per-protocol if vaccinated are higher among per-protocol placebo recipients at
lower (higher) risk for infection, i.e., with longer (shorter) infection times. The parameter β1
has a parallel interpretation for per-protocol vaccine recipients.
Models B.1 and B.2 may be equivalently expressed as pattern mixture models, which give
the sensitivity parameters alternative interpretations that may be preferred by some
practioners. For example, with weight (4), B.1 can be re-expressed as
for t ∈ (τ0, τ, such that exp{β0} is the density ratio (comparing the APP and {PP(1) = 0,
PP(0) = 1} subpopulations) of infection at time t divided by this density ratio at time t − 1.
Thus β0 calibrates the discrepancy between the distributions of T(0) for the APP and {PP(1)
= 0, PP(0) = 1} subpopulations.
B.3 specifies the probability a subject is always per-protocol. Instead of specifying πAPP,
alternatively one could specify ØAPP ≡ πAPP/pp1 = P(PP(0) = 1|PP(1) = 1).
Under B.1 and B.2, for z = 0, 1
(5)




Once β0, β1, πAPP are specified, α0 and α1 are identified based on (6), such that  and
 are identified.
Under the base set of assumptions alone, nonparametric bounds for  are achieved by
setting πAPP to its smallest possible value and βz to −∞ and ∞, i.e.,
 and , where  is the αth percentile
of , for z = 0, 1. Define πmin ≡ max{0, pp0 + pp1 − 1}, the smallest possible value
of πAPP. If πmin = 0, then the bounds for  are the uninformative values 0 and 1. If
πmin > 0, then , where
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for t ≥ τ0 and z = 0, 1. These bounds determine the nonparametric bounds for SCEAPP(t) for
any contrast function h(·, ·) satisfying the properties described in Section 2, equal to
(9)
These bounds are nonparametric because no parametric modeling assumptions are used in
expressing the bounds or in the procedures for estimating them (e.g., B.1–B.3 are not
needed). The Supplementary Materials (Section 2) contain a proof of (8).
Assumption set B (add AM). The same approach is used when AM is added, with the only
difference being that the amount of possible post-randomization selection bias is reduced. In
particular, πAPP is now constrained between max{0, S0(τ0) + pp1 − 1} and min{pp0, pp1}.
In addition, in B.2 the weight function w1(t; α1, β1) = P(A(0) = 1|T(1) > τ0, T(0) > τ0, A(1)
= 1, T(1) = t)P(T(0) > τ0|T(1) > τ0, A(1) = 1, T(1) = t), and by AM the first conditional
probability is known to be one.
The nonparametric bounds for the APP estimand under assumption set B are as in (8) and
(9) with πmin modified to πmin = max{0, S0(τ0) + pp1 − 1}, and are always at least as narrow
as those under assumption set A. If there is nonadherence under treatment z = 0 such that
pp0 < S0(τ0), then τAPP has a narrower range via the extra assumption AM, yielding
narrower bounds (if πmin > 0). This occurs in the Thai trial example.
Assumption set C (add SM, AM). Again the same approach is used as under assumption sets
A and B, with the amount of possible post-randomization bias further reduced by the
constraint max{0, S0(τ0) + pp1 − S1(τ0)} ≤ πAPP ≤ {pp1, pp0}. Under SM, PP(1) = A(1),
which simplifies the interpretation of β0 to reflect the association of infection risk of per-
protocol placebo recipients with adherence if vaccinated. The nonparametric bounds are the
same as above with πmin replaced with πmin = max{0, S0(τ0) + pp1 − S1(τ0)}.
Assumption set D (add SM, EA). By EA, w0(t; α0, β0) in B.1 equals P(T(1) > τ0|T(0) >
τ0,A(0) = 1, T(0) = t), which by SM equals one. Therefore . In
addition, by EA model B.2 is expressed as w1(t; α1, β1) = P(T(0) > τ0|T(1) > τ0,A(1) = 1,
T(1) = t), which we again model with the modified inverse logit function (4). SM and EA
together identify πAPP as πAPP = pp0. Therefore only B.2 among the models (B.1, B.2, B.3)
is needed, and simple calculations show that
(10)
where α1 is the solution of (6) with z = 1 and πAPP = pp0. The nonparametric bounds for
 (for t ≥ τ0) are given by (8) with πmin = pp0 and z = 1.
Nonparametric bounds under alternative assumption sets. Zhang and Rubin (2003) and
Chiba (2012) derived nonparametric bounds for the average causal effect in “always
survivors” under different assumptions than SM, AM, and EA. While we chose our
assumption sets to be maximally relevant for vaccine trials, these alternative assumptions
may also be plausible for some vaccine trials, and yield alternative nonparametric bounds
for SCEAPP (t). Seven alternative assumption sets, their interpretations and plausibility for
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RV144, and the corresponding nonparametric bounds are described in Supplementary
Materials (Section 3 and Supplementary Table 2).
4.2. Estimands  and 
Assumption set A. The ASA1 estimands are identified using the same models as above,
except the event {PP(0) = 1} is replaced with {T(0) > τ0}:
B.1': P(PP (1) = 1|T(0) > τ0, .
B.2': P(T(0) > τ0|PP(1) = 1, .
B.3': πASA1 ≡ P(PP(1) = 1, T(0) > τ0) is fixed and known.
Again we model each wz(·) as in (4). The sensitivity parameters  have
different interpretations than those under assumption set A; for example  is the log odds
ratio of meeting the PP-criteria under Z = 1 per unit increment of the failure time for
subjects with T > τ0 under Z = 0. The parameter πASA1 is constrained between max{0,
S0(τ0) + pp1 − 1} and min{pp1, S0(τ0)}. Algebra shows that
Nonparametric bounds for SCEASA1(t) are constructed similarly as for SCEAPP (t), replacing
 with  and pp0 with S0(τ0). With πmin ≡ max{0, S0(τ0) + pp1 − 1}, the
bounds for  are informative if πmin > 0, and for t ≥ τ0 equal
Assumption sets B, C, D. Under AM included in B, C, and D, , such
that the identical methods described above for the APP estimand apply.
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4.3. Estimands  and 
The base set of assumptions identify  (by , but not .
Assumption set A. We write
(11)
and use a selection bias model parallel to B.1 and B.1': B.1”:
, where again we specify w0(·) as modified inverse-
logit as in (4).
Straightforward calculation using (11) and B.1” shows that
(12)
where  is the solution to .
Since  is identifed from the base set of assumptions, nonparametric bounds for
SCEPP1(t) derive from nonparametric bounds for . By similar derivations used in the
proof of (8) in the Supplementary Materials, the bounds equal
(13)
The width of the bounds increases with the risk of early failure or nonadherence. In many
applications, S0(t)/pp1 > 1 for most or all t, such that the upper bound is one.
Assumption set B (add AM). Under AM, , H(0)
= 1) for t ≥ τ0, where {H(0) = 1} = {T(0) ≤ τ0} ∪ {PP(0) = 1}. With  the
distribution of T(0) conditional on H(0) = 1, we use the selection model:
B.2”:  for t ≥ 0, such that
(14)
Simple calculations show that P(H(0) = 1) = 1 − S0(τ0) + pp0 and
 for t ≥ τ0. With w0(·)
again the inverse-logit function,  is the log odds of PP(1) = 1 given H(0) = 1 and T(0) = t
versus t − 1. In many applications {H(0) = 1} ≈ {PP(0) = 1} due to a much larger number of
subjects in {PP(0) = 1} than in {T(0) ≤ τ0}, in which case  has an interpretation very close
to that of β0 for the APP estimand under assumption set A. (This close approximation attains
in the Thai trial, where  and .)
The nonparametric bounds are , where
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The bounds (15) are at least as sharp as those computed under the base set, (13).
Assumption set C. When SM is added, the methods are identical to those under assumption
set B. Under assumption sets B and C,  if πAPP = pp1, which
occurs if PP(1) = 1 implies PP(0) = 1. Moreover,  if πAPP =
pp1 or PP(0) ⊥ T(1)|PP(1) = 1 (i.e., β1 = 0 in B.2).
Assumption set D (add SM, EA). Under AM, . SM and EA
imply πAPP = pp0 and , such that  is identified by
(16)
and there are no sensitivity parameters. Therefore under SM and EA, the non-causal
estimand  is corrected to a causal one through the
adjustment constant pp0/pp1, which is ≤ 1. The formula shows how the correction depends
on differential rates of early failure and adherence. Under assumption set D,
 if and only if pp0 = pp1, which is testable.
Table 2 lists the four assumption sets for each of the three estimands.
5. Maximum Likelihood Estimation and Uncertainty Intervals
We consider inference about the estimands SCE#(t). Estimators of SCE#(t; γ) for a fixed
value of the sensitivity parameter(s) γ are described in Section 5.1. Because γ is not
identifiable, we recommend reporting an estimated ignorance interval, i.e., a set of point
estimates  with γ varied over a selected region Γ. Ignorance intervals express
ambiguity about the parameter of interest due to partial identifiability; in contrast, traditional
confidence intervals (given a particular fixed γ) express ignorance/ambiguity due to
sampling variability only. Associated with ignorance regions, in Section 5.2 we describe
procedures for constructing uncertainty intervals that incorporate imprecision due to
sampling variability as well as to lack of identifiability.
5.1. Estimation of SCEAPP (t), SCEASA1(t), and SCEPP1(t)
Given fixed γ, for each estimand and assumption set, maximum likelihood estimators
(MLEs) of SCE#(t; γ) are constructed by plugging in MLEs for the quantities given in
Section 4. Kaplan-Meier estimates (nonparametric MLEs) can be used to estimate
, , and Fz(t), for z = 0, 1. MLEs for ppz are the proportion of subjects
assigned treatment z with PP(z) = 1. Estimation proceeds by fixing sensitivity parameters
and then solving for unknown parameters. For example, for the APP estimand under
assumption set A, using (6) and fixing βz and πAPP, the MLE of αz is the solution to
. Then, the MLE of  is obtained by
plugging the MLEs into (7). The MLEs of the nonparametric bounds are obtained by
substituting MLEs into (8) and (9). Estimation of the other estimands and under different
assumption sets proceeds in a similar fashion.
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As shown in Table 2, the sensitivity parameters π# are constrained by functions of the
identifiable parameters pp1, pp0, and S0(τ0). Therefore the data may contradict certain
choices of τ#, precluding estimation via plug-in MLEs in the above equations. Accordingly,
we suggest using the MLEs of pp1, pp0, and S0(τ0) in the inequality bounds, as listed in
Supplementary Table 3. This approach is equivalent to re-parametrizing with an
unconstrained sensitivity parameter (Supplementary Material, Section 3).
The data may violate an assumption that is nonetheless assumed. For example, assumption
set D implies pp0 ≤ pp1, but in the Thai trial . In such cases the estimation
procedure uses constrained MLEs; in this example, for the PP1 estimand,  is forced
to unity such that  by equation (16).
5.2. Estimated Ignorance Intervals and Uncertainty Intervals
With Γ a specified region of sensitivity parameter values γ and γ0 ∈ Γ the true value, we
consider inference and uncertainty interval estimation for SCE#(t; γ0) for fixed t ≥ τ0. For
each fixed γ ∈ Γ, the bootstrap can be used to estimate the variances of  and
, as well as to construct percentile confidence intervals for  and SCE#(t;
γ). To compute estimated ignorance and uncertainty intervals, we use the fact that for each
estimand and assumption set,  is monotone in γ. With one sensitivity parameter
such as γ = β1, monotonicity implies that the extreme estimates  are obtained by
setting β1 to its extreme values. With three sensitivity parameters such as γ = (β0, β1, πAPP),
monotonicity implies that the extreme estimates  are obtained by setting each of
the three parameters to an extreme value; for example, Section 4.1 described how to achieve
this for the APP estimand. For a given analysis [estimand, assumption set, contrast function
h(.,.)], suppose the values γl and γu in Γ yield the minimum and maximum estimates
. The estimated ignorance interval is computed as .
Supplementary Table 3 lists the data-dependent values of γl and γu to use in a standard
plausible-range sensitivity analysis that we propose in Section 5.3.
Following Vansteelandt et al. (2006, Section 4.1), a (1 – α) × 100% pointwise uncertainty
interval is defined by random limits L#(t) and U#(t) satisfying
where  indicates that probabilities are taken under . Such intervals are of interest
because they contain the true SCE#(t; γ0) with probability at least 1 − α. Imbens and Manski
(2004) and Vansteelandt et al. (2006, Section 4.1) provided a method for obtaining
estimated pointwise uncertainty intervals (henceforth EUIs), and showed that the EUIs have
asymptotically correct coverage under the assumptions that  is
asymptotically normal and γl and γu are independent of the observed data law. If γl and γu
are selected based on the observed data (as done, for example, with our standard plausible-
range sensitivity analysis proposed below), then the bootstrap can be used to provide
approximately correct EUIs (Vansteelandt et al. 2006, page 971); the bootstrap accounts for
the sampling variability in γl and γu by recomputing γl and γu within each bootstrap iteration
(see Section 3 in the Supplementary Material). Specifically, a bootstrap estimated (1 − α) ×
100% EUI for SCE#(t; γ0) is constructed as the union of the two bootstrap percentile (1−α)
×100% 1-sided confidence intervals for SCE#(t; γ) computed at γ = γl and at γ = γu,
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respectively. Here the significance level α does not need to be divided by two provided
SCE#(t; γu) > SCE#(t; γl) (Imbens and Manski, 2004), which occurs for all of the proposed
sensitivity analysis methods because γl ≠ γu and SCE# (t; γ) is strictly monotone in γ. Based
on similar derivations used in Shepherd, Gilbert, and Lumley (2007), asymptotic normality
of  holds under simple conditions (provided in Supplementary
Table 4), and their simulation studies plus those of SGD demonstrate satisfactory
performance of the bootstrap, including nominal coverage probabilities of confidence
intervals given fixed values of γ.
The null hypothesis  for some fixed constant SCE* can
be tested based on the EUI, by rejecting  if the (1 − α) × 100% EUI excludes SCE*. The
corresponding 2-sided p-value equals the smallest α such that the (1−α)×100% EUI
excludes SCE*. This testing procedure has size bounded above by α, and thus has the
desirable 1:1 correspondence with the EUIs. Alternatively,  can be tested directly using
the infimum test of Todem et al. (2010), and their test inverted to obtain an (1 − α) × 100%
EUI for SCE#(t, γ0), namely the set of SCE* where  is not rejected at significance level
α.
5.3. A Suggested Standard Sensitivity Analysis
Given that it is often challenging to obtain consensus among experts about the plausible
range of sensitivity parameters, it may be useful to develop standards that, while somewhat
arbitrary, can be uniformly applied and make causal per-protocol analyses more objective
and interpretable. We suggest one possible standard, where the odds ratios exp(β0) and
exp(β1) are varied between 1/B and B per increment  in failure time T(0) and T(1), where
the scalar  and the bound B are selected by subject matter experts based on the context of
the study (following the approach of Shepherd, Gilbert, and Mehrotra, 2007). For example, 
may simply be a 1-year interval. The plausible upper bounds for πAPP and πASA1 are set at
 and , respectively, the MLEs of the maximum possible
value. For assumption set A we suggest using the more plausible lower bound for πAPP of
, corresponding to the MLE of πAPP if PP(0) and PP(1) were independent (negative
correlation seems highly implausible). Similarly, we suggest using  as the
plausible lower bound for πASA1. Under assumption sets B and C we suggest setting πAPP
and πASA1 at the MLEs of the minimum possible values, which vary by assumption set,
since AM and SM greatly constrain the ranges for πAPP and πASA1 (values listed in
Supplementary Table 3). We also suggest reporting the nonparametric bounds as worst-case
scenarios.
6. Example
We apply the above methodology to evaluate per-protocol vaccine efficacy in the Thai trial,
using the vaccine efficacy contrast function h(x, y) = 1 − (1 − x)/(1 − y). The protocol
definition of adherence required receiving all six immunizations at the four scheduled
immunization visits within allowable visit windows by τ0 ≡ 6.21 months after
randomization. The trial followed subjects for HIV infection up to the terminal study visit at
42 months, and we focus on a time-point near the end of evaluation, t = 39 months. Thus, we
denote the estimands of interest as VE#(39; γ0) = SCE#(39; γ0). First we illustrate
application of all of the methods, and second we evaluate the plausibility of each extra
assumption, and, based on this assessment, conduct a substantively relevant sensitivity
analysis. We use the yearly scale  to define the maximum plausible selection bias odds
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ratio of 1/B or B, with B = 1.5. We construct EUIs and tests for  using the approach
described in Section 5.2.
The choice of B is important as it strongly affects the width of ignorance intervals and EUIs.
Given the authors experience in HIV vaccine efficacy trials, and our lack of involvement in
RV144 until after the primary publication, we counted ourselves as suitable experts to
specify B. Because the infection rates by τ0 were very low, per-protocol status is
approximately equivalent to adherence status, such that B essentially measures the maximal
association, within individuals adherent under the assigned treatment arm, of their infection
times with adherence under the opposite treatment arm. Our choice of B = 1.5 reflects our
belief that infection time had low association with adherence under the un-assigned arm in
subjects already known to be adherent under the assigned arm. Moreover, our choice of
relatively small B was influenced by the fact that infection times are the outcome of many
constituent factors including demographics, host genetics, sexual behavior, and prevalence/
characteristics of HIV in sexual partners, and these factors had limited heterogeneity in this
general population study with low representation of extremely high risk groups and with low
observed heterogeneity in infection risk (Rerks-Ngarm et al. 2009). Given the challenge in
selecting B, we recommend reporting results for both the plausible range and nonparametric
bounds sensitivity analyses.
Figure 1 shows estimated ignorance intervals and 95% EUIs for V E#(39; γ0) for the three
estimands under each assumption set. The methods are applied using both the maximum
possible sensitivity parameter ranges (nonparametric bounds) and the maximum plausible
ranges according to the suggested standard (semiparametric sensitivity analysis). For the
nonparametric bounds approach, for each estimand and under assumption sets A, B, and C,
the range of point estimates is large, extending to negative infinity. However, under
assumption set D the estimated ignorance interval collapses to a single point, the point
estimate under the naive analysis that uses the estimator . The
plausible-range results show that the AM assumption (but not SM) leads to substantially
narrower estimated ignorance intervals and EUIs. In addition, under assumption sets A, B,
and C, these intervals are much narrower for the plausible-range sensitivity analysis than for
the nonparametric bounds analysis, showing a major benefit from leveraging plausible
assumptions.
Using assumption set A, Figure 2 shows the point and 95% confidence interval estimates for
V EAPP (39; γ) as a function of the fixed sensitivity parameters γ = (β1, β0, ϕAPP), varied
over the suggested standard plausible region Γ. As indicated by the dark shaded region, for
the analysis to demonstrate significant benefit V EAPP (39; γ) > 0, the sensitivity parameters
must satisfy ϕAPP < 0.95 and (exp(β1), exp(β0)) in the upper-left triangle with large values of
exp(β1) and small values of exp(β0). Using estimates , , and , and under
assumption sets B and C, ϕAPP is constrained to be within [0.9984, 1] and [0.9992, 1],
respectively. Hence, a sensitivity analysis under B or C corresponds approximately to Figure
2, ϕAPP = 1.0. The reduced variability of the vaccine efficacy estimate over the range
induced by AM is apparent.
Figure 3 shows the parallel results for V EASA1(39; γ), indicating significant benefit V
EASA1(39; γ) > 0 for values of  less than about 0.7. The odds ratio  being
less than 1 reflects the premise that placebo recipients with longer infection times have
lower odds of being per-protocol under vaccine than placebo recipients with shorter
infection times. This would be plausible if higher risk per-protocol subjects are less likely to
be per-protocol if randomized to the other arm than lower risk per-protocol subjects. Thus if
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there is any evidence for a beneficial vaccine effect for the ASA1 subgroup, it is highly
sensitive to small amounts of selection bias.
Figure 4 shows the results for V EPP1(39; γ) under assumption set A and under B or C,
demonstrating significant benefit V EPP1(39; γ) > 0 for all values of
. Because  has a similar interpretation as β0 for the APP
estimand, the significant effect is robust under a premise that per-protocol placebo recipients
with shorter infection times would not have a higher odds of being per-protocol under
vaccine than per-protocol placebo recipients with longer infection times.
Next, we evaluate the plausibility of the identifiability assumptions. The consistency part of
SUTVA holds because the trial is randomized and only one vaccine regimen was
administered in a uniform manner, and the no interference part of SUTVA is plausible
because the study sites were geographically dispersed across Thailand, the annual HIV
incidence was low (0.2%), and only 1–2 clusters of infected subjects were identified.
Ignorable treatment assignment is plausible because there were no recorded problems with
the validity of the randomization. Random censoring is difficult to evaluate, but the impact
of any violation of this assumption is minimized by the high rates of participant retention
(10% drop-out by the terminal visit). SM is plausible, given that fewer subjects were
observed to be infected by τ0 in the vaccine than placebo group (5 versus 10), with
 and . AM is plausible but EA is not, given that, among those
with an HIV negative test result at the Week 24 visit, the adherence rate was higher in the
placebo than vaccine group: 5565 of 7317 (76.1%) versus 5285 of 7234 (73.1%) adherent
(Chi-squared test p < 0.0001).
Assumption set C is therefore the strongest plausible assumption set, and we will interpret
the results based on this set. From Figure 1, the estimated ignorance interval (95% EUI) for
per-protocol causal vaccine efficacy is 18% to 23% (−30% to 51%) for each of the APP and
ASA1 estimands, such that there is little evidence for positive vaccine efficacy after
accounting for potential selection bias. In contrast, the estimated ignorance interval (95%
EUI) for V EPP1(39; γ0) is 34% to 39% (4% to 95%), indicating evidence for significant
positive vaccine efficacy among those who were (or would have been) per-protocol when
randomized to vaccine.
The hypothesis tests based on EUIs yield 2-sided p-values of 0.52 for the APP and ASA1
estimands and 0.03 for the PP1 estimand.
To assess per-protocol vaccine efficacy over time, we repeated the above analyses for a grid
of fixed times t shortly after τ0 through to τ (9 to 39 months). Supplementary Figures 1–12
show the estimated ignorance intervals and 95% EUIs for V E#(t; γ0) and for the constituent
survival curves , under each assumption set. Under sets B–D, the estimates of V
E#(t) decline over time for each estimand, with borderline significant V E#(t) > 0 through
about 12–15 months for the plausible range analysis.
In conclusion, the causal sensitivity analysis provides a more interpretable assessment of
per-protocol vaccine efficacy than the non-causal result originally reported in Rerks-Ngarm
et al. (2009). Moreover, it provides a more complete account of uncertainty than the original
analysis, by accounting for partial non-identifiability as well as for sampling variability. The
original estimate of non-causal per-protocol vaccine efficacy was , 95% CI −16%
to 51%, p = 0.19, compared to the causal estimates of  to 23% (for the APP and
ASA1 estimands), with 95% EUI −30% to 51%, p = 0.52. Thus, the causal analysis provides
less evidence for beneficial vaccine efficacy through 39 months in subjects adherent to the
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full set of immunizations, in both the magnitude and precision of the point estimates.
However, the time-dependent analysis indicates marginally significant positive per-protocol
vaccine efficacy over the first 12–15 months after accounting for plausible levels of
potential selection bias.
For the APP estimand, the estimated ignorance intervals and EUIs are very wide under
assumption set A, for both the semiparametric and nonparametric bounds, raising the
question as to what are scenarios where the estimates will be sufficiently narrow to make
precise conclusions. In general, both bounds will be narrow when the per-protocol
probabilities and the event rates are high in both groups, in which case there is little room
for selection bias. In the rare event setting such as for RV144, the semiparametric bounds
may still be informatively precise if the per-protocol rates and numbers of events are large.
To demonstrate this, Supplementary Figure 13 shows the identical analysis presented in
Figure 1 for a second HIV vaccine efficacy trial with a very similar study design, Vax004
(Flynn et al. 2005), which had much higher per-protocol rates (92.6% and 93.0% in the
vaccine and placebo groups) and 3-fold more events (368 HIV infections). The
semiparametric estimated ignorance intervals and EUIs are much narrower than for RV144,
demonstrating the impact of higher per-protocol rates and greater event numbers,
respectively. However, the nonparametric bounds under assumption set A are still very
wide, illustrating that in rare event settings the nonparametric bounds are typically
uninformative.
7. Discussion
In clinical trials with survival time endpoint, the standard analysis of per-protocol treatment
efficacy contrasts estimates of  and . Imbalances in predictors of the
survival endpoint between the comparator groups {PP = 1, Z = 1} and {PP = 1, Z = 0} may
easily occur, which renders the analysis non-causal and potentially misleading. Therefore, it
is of interest to assess alternative per-protocol estimands that measure a causal effect of
treatment. However, such estimands are not identifiable from the observable data plus
standard assumptions, which makes a sensitivity analysis generally warranted, and motivates
this work.
We defined three survival causal effect (SCE) per-protocol vaccine/treatment efficacy
parameters of interest– SCEAPP(t), SCEASA1(t), SCEPP1(t)– and procedures for drawing
inferences about these estimands under different assumption sets and specified regions for
fixed sensitivity parameters. The estimands have di erent interpretations and hence different
utilities. The APP estimand may be particularly useful for guiding future research and
policies for using the vaccine/treatment, given that always compliers (i.e., always per-
protocol subjects) are those who can be expected to adhere to the treatment, and the level of
efficacy in this subgroup is an important input parameter for models that predict the
treatment's effectiveness in various settings where the adherence pattern may differ from
that observed in the clinical trial. The ASA1 estimand measures the treatment effect for the
always-survivors who would take treatment, regardless of their adherence under control, and
may also be a useful input into treatment effectiveness models. Compared to the APP
estimand, the ASA1 estimand has advantage of identifiability under weaker assumptions,
and disadvantage that the ASA1 subpopulation has a less straightforward interpretation,
equal to the union of the always per-protocol subpopulation and the always-survivors who
would adhere to Z = 1 but not to Z = 0. Reporting results for both estimands may be useful
for assessing whether and to what extent treatment efficacy is associated with adherence
under Z = 0. For blinded trials of non-toxic treatments, the estimands should be
approximately equal, and in fact are exactly equal under the Adherence Monotonicity
assumption that adherence to Z = 1 implies adherence to Z = 0. The PP1 estimand is least
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useful for evaluating treatment efficacy because by construction it favors the Z = 1 arm,
such that its main value may be for assessing the amount of efficacy received for the
observable subgroup of subjects who are per-protocol under active treatment Z = 1. An
appeal of the PP1 estimand is that Z = 1 subjects in the PP1 cohort can be directly observed,
and hence directly studied and characterized.
For trials with objective to evaluate per-protocol treatment efficacy, it is valuable to
routinely report a sensitivity analysis of these causal estimands, at least for the APP and
ASA1 estimands. Given that estimated uncertainty intervals are wider than confidence
intervals, for trials where assessment of per-protocol treatment efficacy is a key objective, it
may be prudent to increase the sample size accordingly, recognizing that increasing the
sample size alone may not be sufficient to obtain narrow uncertainty intervals if the
probability of being per-protocol is low.
Ideally, the per-protocol sensitivity analysis would account for potential bias due to
unmeasured variables, after adjusting for potential bias due to observed variables. The
sensitivity analysis methods developed in this article could be extended to adjust for
observed covariates in a number of ways. One modification would be based on the fact that,
for all assumption sets and for both the nonparameteric bounds and semiparametric
sensitivity analysis approaches, the causal estimands SCE#(t; γ0) are functions of two types
of terms: (1) fixed values of sensitivity parameters and models of selection bias; and (2)
survival curves , , and Sz(t) that are identified from the observed data
under the base set of assumptions. Therefore, the inferential methods described in Section 5
may be modified to adjust for covariates by replacing the Kaplan-Meier estimates of the
above survival curves with covariate-adjusted estimates, for example via the method
described in Hernán (2010).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Estimated ignorance intervals (thick segments) and 95% EUIs (thin segments) for (a) V
EAPP (39; γ0), (b) V EASA1(39; γ0), (c) V EPP1 (39; γ0) under assumption set A (base set), B
(base set + AM), C (base set + SM, AM), D (base set + SM, EA). Left (right) vertical lines
are nonparametric bounds (semiparametric bounds with plausible ranges), where arrows
indicate extension to –∞ (to a negative number < −1.0).
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Contour plots of  (39; γ) for γ = (β1, β0, ϕAPP) varying over the plausible region Γ,
under assumption set A. Dark shaded regions indicate γ values at which V EAPP (39; γ) is
significantly > 0. ϕAPP = 0.77 corresponds to PP(1) ⊥ PP(0). When ϕAPP = 1, results only
vary with β0; thus the OR1 parameter is irrelevant in the lower-middle contour plot, and the
lower-right plot shows  (39; γ) (γ = β0) with 95% confidence intervals as a function
of exp(β0).
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Contour plots (left and middle) of  (39; γ) for  varying over the
plausible region Γ, under assumption set A. Dark shaded regions indicate γ values at which
V EASA1(39; γ) is significantly > 0. The right plot shows (39; γ) with 95%
confidence intervals as a function of  when ϕASA1 = 1.
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Estimates of V EPP1(39; γ) and 95% confidence intervals for  values varying over the
plausible range Γ, under assumption set A (base set; left panel) and under assumption set B
or C (base set + AM or base set + SM, AM; right panel).
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Table 1
Culling of the MITT Cohort to Form the PP Cohort in the RV144 Thai Trial*
Reason for Exclusion from the PP Cohort MITT Vaccine MITT Placebo
Diagnosed with HIV by the week 24 visit 5/8197 (0.06%) 10/8198 (0.12%)
Not diagnosed with HIV by the week 24 visit but nonadherent (A = 0)
 Dropped out before week 24 visit 67/8197 (0.82%) 70/8198 (0.85%)
 Reached week 24 visit HIV negative but nonadherent to vaccination visits: 1949/8197 (23.8%) 1752/8198 (21.4%)
　 All 4 with ≥ 1 outside window 749 671
  Received 3 vaccinations 80 68
  Received 2 vaccinations 81 76
  Received 1 vaccination 146 134
  Received 0 vaccinations 2 4
  Other reasons (mainly outside window) 891 799
Total Culled Out 2021/8197 (24.7%) 1832/8198 (22.3%)
*
Group-imbalances in prognostic factors for HIV infection could arise due to differences (by treatment assignment) in probabilities of any of the
events (1) HIV infection diagnosis by the Week 24 visit, (2) dropout by the Week 24 visit, or (3) reaching the Week 24 visit at-risk but nonadherent
to the vaccinations.
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Table 2
Assumption Sets Under Which the Sensitivity Analysis May Be Performed
Assumption Sets: S. Pars. γ Γ (Maximum Possible- Nonparametric Bounds) Γ (Maximum Plausible*)
Estimand SCEAPP(t; γ)
A. B.1, B.2, B.3 β0, β1 −∞ < βZ < ∞
π APP max{0, pp0 + pp1 − 1} ≤ πAPP ≤ min{pp0, pp1} pp1pp0 ≤ πAPP ≤ min{pp0, pp1}
B. B.1, B.2, B.3, SM, AM β0, β1 −∞ < βZ < ∞
π APP max{0, S0(τ0) + pp1 − 1} ≤ πAPP ≤ min{pp0, pp1} same as maximum possible range
C. B.1, B.2, B.3, SM, AM β0, β1 −∞ < βZ < ∞
π APP max{0, S0(τ0) + pp1 − S1(τ0} ≤ πAPP ≤ min{pp0, pp1} same as maximum possible range
D. B.2, SM, EA β 1 −∞ < βZ < ∞
Estimand SCEASA1(t; γ)
A. B.1', B.2', B.3'
, 
π ASA1 max{0, S0(τ0) + pp1 − 1} ≤ πASA1 ≤ min{S0(τ0), pp1} pp1S0(τ0 ≤ πASA1 ≤ min{S0(τ0), pp1}
B. B.I', B.2', B.3', AM
, 
π ASA1 same as in B. for APP same as in B. for APP
C. B.1', B.2', B.3', SM, AM
, 
π ASA1 same as in C. for APP same as in C. for APP




C. B.2", SM, AM
D. SM, EA None N/A (Full Identifiability) N/A
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*
B > 1 is a specified constant;  is a specified interpretable time-increment such as 1 year or the fixed follow-up period.
J Am Stat Assoc. Author manuscript; available in PMC 2014 January 01.
